SIGN UP TO VIEW THE FULL ARTICLE

Receive a 90-day free trial of Celltelligence and get instant access to our full offering.


EMAIL BLASTS

Curated cell therapy industry news in your inbox multiple times each week

SEARCHABLE LIBRARY

A full archive of cell therapy news, insights, and context

THE MAP

A 24/7 information center that lets you make unique connections

The price for access is $0.00.

Do you have a discount code? Click here to enter your discount code.


Account Information

LEAVE THIS BLANK

By selecting this, I agree to receive emails from celltelligence.com.


Already have an account? Log in here

Autolus’s Industrialized Manufacturing Process for Obe-cel; Updated Results From Autolus’s Ph1 ALLCAR19 and Ph1 CARPALL Trials; ASH 2021 Day 3 Autolus Investor Event

Here is a brief preview of this blast: On Monday, December 13, Autolus held their investor event (press release / presentation) comparing obe-cel’s (CD19 CAR-T; formerly AUTO1) Ph1 ALLCAR19 study and Ph1b/2 FELIX trial in r/r B-ALL. Moreover, management provided updated preclinical and clinical data for obe-cel’s ALLCAR19 iNHL cohort and AUTO1/22 (CD19 x CD22 CAR-T) in r/r pediatric ALL. Below, Celltelligence provides insights on obe-cel’s industrialized manufacturing process, while discussing Autolus’s AUTO1/22 indication strategy.

About The Author

The Celltelligence Team

|
Content Leads & Contributors
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.